5FR Stock Chart & Stats
€8.60
€0.15(1.78%)
At close: 4:00 PM EDT
€8.60
€0.15(1.78%)
Day’s Range― - ―
52-Week Range€6.15 - €9.90
Previous CloseN/A
Volume0.00
Average Volume (3M)36.00
Market Cap
€726.88M
Enterprise Value€167.99K
Total Cash (Recent Filing)€32.61B
Total Debt (Recent Filing)€74.18B
Price to Earnings (P/E)21.9
Beta0.32
Next Earnings
Aug 07, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)79.34
Shares Outstanding76,771,484
10 Day Avg. Volume106
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio3.13
Price to Book (P/B)1.34
Price to Sales (P/S)1.01
P/FCF Ratio-37.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.56Price Target Upside34.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.48
Revenue Forecast (FY)€709.22M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent top-line expansion over several years demonstrates durable demand for Menicon's vision-care products and supports scale advantages. A growing revenue base provides capacity to invest in R&D, expand distribution, and smooth fixed costs, reinforcing long-term competitiveness despite recent growth slowing.
High Gross MarginsSustained gross margins near the mid-50s indicate solid product economics and pricing power in contact lenses and consumables. Strong gross profit provides headroom to absorb SG&A and R&D, supporting product development and margin resilience versus peers in the medical instruments segment over the medium term.
Growing Equity BaseA materially larger equity base strengthens financial flexibility and loss-absorbing capacity, enabling Menicon to fund capex, innovation, or M&A without immediate reliance on new equity. This balance-sheet improvement supports long-term strategic initiatives and reduces insolvency risk compared with a weaker capital base.
Bears Say
Recurring Negative Free Cash FlowRecurrent negative free cash flow signals heavy investment or volatile working capital that undermines internal funding for growth and payouts. Persistent FCF deficits force dependence on external financing or asset sales, constraining strategic optionality and raising execution risk over the medium term.
Rising LeverageHigher absolute debt and a climbing debt/equity ratio reduce financial flexibility and increase sensitivity to interest-rate moves. Greater leverage heightens refinancing and covenant risk, limits capital allocation choices, and can magnify earnings volatility if revenue or margins deteriorate, weakening long-term resilience.
Margin Compression & Earnings QualityFalling net margins and low operating cash flow coverage of reported earnings imply earnings are under pressure and convert poorly to cash. This combination questions profitability sustainability and raises the risk that reported profits overstate durable cash generation needed to fund dividends, buybacks, or reinvestment.
Menicon Co News
5FR FAQ
What was Menicon Co Ltd’s price range in the past 12 months?
Menicon Co Ltd lowest stock price was €6.15 and its highest was €9.90 in the past 12 months.
What is Menicon Co Ltd’s market cap?
Menicon Co Ltd’s market cap is €726.88M.
When is Menicon Co Ltd’s upcoming earnings report date?
Menicon Co Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 5 days.
How were Menicon Co Ltd’s earnings last quarter?
Menicon Co Ltd released its earnings results on May 13, 2026. The company reported -€0.031 earnings per share for the quarter, missing the consensus estimate of €0.004 by -€0.034.
Is Menicon Co Ltd overvalued?
According to Wall Street analysts Menicon Co Ltd’s price is currently Undervalued.
Does Menicon Co Ltd pay dividends?
Menicon Co Ltd does not currently pay dividends.
What is Menicon Co Ltd’s EPS estimate?
Menicon Co Ltd’s EPS estimate is 0.09.
How many shares outstanding does Menicon Co Ltd have?
Menicon Co Ltd has 76,771,484 shares outstanding.
What happened to Menicon Co Ltd’s price movement after its last earnings report?
Menicon Co Ltd reported an EPS of -€0.031 in its last earnings report, missing expectations of €0.004. Following the earnings report the stock price went down -3.165%.
Which hedge fund is a major shareholder of Menicon Co Ltd?
Currently, no hedge funds are holding shares in DE:5FR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Menicon Co Ltd
Menicon Co., Ltd. is a company dedicated to the manufacturing and global distribution of contact lenses and their essential care solutions. The firm supplies its range of eye care products to a diverse network of outlets, including medical facilities like hospitals and ophthalmology clinics, as well as retail channels such as specialized contact lens stores, eyewear retailers, and pharmacies. With a substantial international presence, Menicon extends its reach to over 80 countries, encompassing major markets in the United States, Europe, Oceania, and Asia. This Japanese entity, which was founded in 1943, is based in Nagoya.
5FR Stock 12 Month Forecast
Average Price Target
€11.56
▲(34.45% Upside)
Technical Analysis
HOYA
―
JINS HOLDINGS
―
Japan Eyewear Holdings Co.,Ltd.
―
Mani, Inc.
―
Seed Co., Ltd.
―